Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.40 |
| ▸ | MEN1 | O00255 | 2/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | PKM | P14618 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | TP53 | P04637 | 1/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.30 |
| ▸ | HLCS | P50747 | 1/20 | 0.30 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.30 |
| ▸ | MMP1 | P03956 | 1/20 | 0.30 |
| ▸ | MMP3 | P08254 | 1/20 | 0.30 |
| ▸ | MMP9 | P14780 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5283640 | 0.94 | CYP1A2 (0.36) | ALDH1A1MEN1KMT2AKDM4EMAPT | |
| SCHEMBL2007688 | 0.92 | CYP1A2 (0.39) | ALDH1A1MEN1KMT2AKDM4EMAPT | |
| SCHEMBL20448811 | 0.92 | CYP1A2 (0.39) | ALDH1A1MEN1KMT2AKDM4EMAPT | |
| SCHEMBL7662496 | 0.88 | SMN1; SMN2 (0.34) | ALDH1A1MEN1KMT2AKDM4EMAPT | |
| SCHEMBL23219623 | 0.79 | DAO (0.30) | — | |
| SCHEMBL762450 | 0.79 | — | — | |
| SCHEMBL1643317 | 0.79 | — | — | |
| SCHEMBL31055607 | 0.78 | TERT (0.38) | — | |
| SCHEMBL13661709 | 0.78 | SIGMAR1 (0.33) | — | |
| SCHEMBL14671140 | 0.77 | PRKCA (0.40) | ALDH1A1KDM4EMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7205385-B2 | magnetic resonance imaging agents; poly(amino acid-imaging agent) product can be obtained in high purity without a rigorous purification since all impurities are removed at the monomer synthesis stage | GENERAL ELECTRIC COMPANY (US) | 2007-04-17 | — | — | US | disclosed |
| US-20020058819-A1 | METHOD OF PRODUCING 2,4-OXAZOLIDINEDIONES AND METAL SALTS THEREOF | SUMITOMO CHEMICAL COMPANY, LIMITED | 2002-05-16 | — | — | US | disclosed |
| US-6384231-B1 | CYCLIZATION OF 2 HYDROXYCARBOXYLATE WITH UREA; METAL ALKOXIDE; AROMATIC HYDROCARBON SOLVENT; BY-PRODUCT INHIBITION | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2002-05-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020058819-A1 | METHOD OF PRODUCING 2,4-OXAZOLIDINEDIONES AND METAL SALTS THEREOF | HAO2, AOC2, HAO1 | ALDH1A1 93/4885MEN1 3979/4885KMT2A 1712/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.